Arkema, 2014 Full year results

March 2015

In a volatile macro-economic environment with moderate world growth, financial performance was impacted by challenging market conditions in fluorogases, and, in the second half of the year, in acrylics.

Nevertheless, the majority of our product lines performed well, demonstrating their sound positioning in high added value niche markets; following a more difficult first part of the year, performance in 4th quarter recovered to the same level as last year.

• €5,952 million sales, 1.4% down on 2013 at constant scope of business and foreign exchange rate
• €784 million EBITDA (€902 million in 2013), with €162 million EBITDA in 4Q, at the same level as last year
• 2014 EBITDA margin down at 13.2%, but remains solid in a market environment impacted by fluorogases and acrylics
• €167 million net income Group share, stable compared to 2013

The Board of Directors of Arkema met on 4 March 2015 to close the consolidated accounts of Arkema for 2014 and the annual financial statements of the parent company. At the close of the meeting, Chairman and CEO Thierry Le Hénaff stated: “In a volatile macro-economic environment with moderate world growth, financial performance was impacted by challenging market conditions in fluorogases, and, in the second half of the year, in acrylics.

Nevertheless, the majority of our product lines performed well, demonstrating their sound positioning in high added value niche markets; following a more difficult first part of the year, performance in 4 th quarter recovered to the same level as last year.

Meanwhile, recent months have represented in several respects major steps in the Group’s transformation with the start-up of our plant in Malaysia which positions our Thiochemicals activity very favourably in Asia; our access to a competitive acrylic monomer production source in China with our acquisition of a stake in Sunke; and, of course, the acquisition of Bostik finalised early February with the set-up of financing, the completion of the social process in France, and the approval by antitrust authorities, all of which within a tight timetable.

These investments, together with the in-depth transformation of Arkema's profile in recent years, ideally position the Group on a path for future growth.”